Patient Size-Specific Analysis of Dose Indexes From CT Lung Cancer Screening.

AJR Am J Roentgenol

2 Physics and Biology in Medicine Graduate Program, David Geffen School of Medicine, University of California, Los Angeles, CA.

Published: January 2017

Objective: The U.S. Centers for Medicare & Medicaid Services (CMS) recently approved the use of low-dose CT for lung cancer screening and described volumetric CT dose index (CTDI) requirements. These were based on the National Lung Screening Trial, which used only fixed-tube-current techniques. The aim of this study was to evaluate dose index data from a lung cancer screening program using automatic exposure control (AEC) techniques to ensure compliance with requirements and to correlate dose index values with patient size.

Materials And Methods: CTDI, dose-length product (DLP), and body mass index (BMI) data were collected for 563 lung cancer screening examinations performed with AEC between January 1, 2014, through August 31, 2015. CTDI and DLP were analyzed according to the patient's BMI classification. Results were compared with the CMS requirement that the CTDI for a standard-sized patient (height, 170 cm; weight, 70 kg) be 3.0 mGy or less, with adjustments for patients of different sizes. For a subset of patients, the average water-equivalent diameter and size-specific dose estimate were estimated.

Results: The average CTDI for a standard-sized patient was 1.8 mGy, which meets CMS requirements. CTDI values were lower for smaller patients and higher for larger patients. Overall, the mean CTDI and DLP were 2.1 mGy and 74 mGy⋅cm, respectively. The size-specific dose estimate for the average water-equivalent diameter (27.5 cm) of the patient subset was 2.6 mGy.

Conclusion: The screening protocols using AEC resulted in CTDI values that were compliant with CMS requirements. CTDI values greater than 3.0 mGy were only observed for overweight or obese patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675046PMC
http://dx.doi.org/10.2214/AJR.16.16082DOI Listing

Publication Analysis

Top Keywords

lung cancer
16
cancer screening
16
ctdi values
12
ctdi
9
ctdi dlp
8
ctdi standard-sized
8
standard-sized patient
8
average water-equivalent
8
water-equivalent diameter
8
size-specific dose
8

Similar Publications

Chemotherapy is widely used to treat lung adenocarcinoma (LUAD) patients comprehensively. Considering the limitations of chemotherapy due to drug resistance and other issues, it is crucial to explore the impact of chemotherapy and immunotherapy on these aspects. In this study, tumor samples from nine LUAD patients, of which four only received surgery and five received neoadjuvant chemotherapy, were subjected to scRNA-seq analysis.

View Article and Find Full Text PDF

Importance: Radiotherapy (RT) plan quality is an established predictive factor associated with cancer recurrence and survival outcomes. The addition of radiologists to the peer review (PR) process may increase RT plan quality.

Objective: To determine the rate of changes to the RT plan with and without radiology involvement in PR of radiation targets.

View Article and Find Full Text PDF

Antibody-drug conjugates (ADCs) represent a novel class of targeted anti-tumor medications that utilize the covalent linkage between monoclonal antibodies and cytotoxic agents. This unique mechanism combines the cytotoxic potency of drugs with the targeting specificity conferred by antigen recognition. However, it is essential to recognize that many ADCs still face challenges related to off-target toxicity akin to cytotoxic payloads, as well as targeted toxicity and other potential life-threatening adverse effects, such as treatment-induced interstitial lung injury.

View Article and Find Full Text PDF

Lung adenocarcinoma (LUAD) represents one of the most common subtypes of lung cancer with high rates of incidence and mortality, which contributes to substantial health and economic demand across the globe. Treatment today mainly consists of surgery, radiotherapy, and chemotherapy, but their efficacy in advanced stages is often suboptimal and emphasizes the clear need for new biomarkers and therapeutic targets. Using comprehensive bioinformatics analyses consisting of the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), Human Protein Atlas (HPA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC), immune infiltration analysis and functional enrichment analysis, and single-cell analysis, we examined the potential of keratin 18 (KRT18) as a candidate biomarker in advanced LUAD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!